Clinical Trials
312 trialsAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
BM7PE
Oslo University Hospital
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MEDIOLA
AstraZeneca
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
University of Southern California
LIBRETTO-001
Eli Lilly and Company
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Institutes of Health Clinical Center (CC)
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Roswell Park Cancer Institute
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
LIBRETTO-121
Eli Lilly and Company
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
CheckMate040
Bristol-Myers Squibb
CheckMate 9N9
Bristol-Myers Squibb
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
NantCell, Inc.
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
CLAUDIO-01
Sotio Biotech Inc.
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Georgetown University
Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
BioNTech SE
TACTOPS
Baylor College of Medicine
ConsortiumIO
Vedanta Biosciences, Inc.
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Parpvax
University of Pennsylvania
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Emory University
GLIMMER-01
Palleon Pharmaceuticals, Inc.
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer
University of Chicago
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Nektar Therapeutics
TACTIC-2
Triumvira Immunologics, Inc.
ARROW
Hoffmann-La Roche
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Aprea Therapeutics
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Precision Biologics, Inc
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Thomas Jefferson University